Tumors of the Brain

Abstract

The annual SEER Cancer Statistics Review (CSR) contains incidence, mortality, prevalence, and survival statistics from 1975 through the most recent year for which data are available. This report is published by the Surveillance Research Program of the National Cancer Institute, which manages the Surveillance, Epidemiology, and End Results (SEER) Program. The scope and purpose of the CSR follow a report to the Senate Appropriations Committee (Breslow, 1988), which recommended that a broad profile of cancer be presented regularly to the American public.The SEER program is an authoritative source of information on cancer incidence and survival in the United States. SEER collects and publishes these statistics from population-based registries covering 30% of the US population. The 18 SEER registries routinely collect data on patient demographics, primary tumor site, tumor morphology, extent of disease, first course of treatment, and active follow-up for vital status. Detailed information describing these fields can be found at https://seer.cancer.gov/resources/. This report presents statistics on 29 primary sites and subsites, organized into site-specific chapters. Detailed statistics on cancer incidence, mortality, survival, and prevalence are reported by sex, race and ethnicity, age, stage at diagnosis, and geographic area. Information on tumor morphology is also presented. In addition, the CSR features a chapter on adolescent and young adult cancers and a chapter on childhood cancers. Information on some rare cancers can be found in the summary tables of section I. For a detailed list of primary sites, the summary tables provide incidence and death rates for the most recent 5-year period, trends from 1975 to the most recent year, median age at diagnosis, median age at death, and survival rates.Delay-adjusted cancer incidence rates are a distinctive feature of the CSR. Delay-adjustment corrects the current case count to account for underreporting and corrections to the data. The final delay-adjusted rates are valuable in more precisely estimating trends.

Characteristics of Neurological Deficits in Intracranial Tumors: A Literature Review

“…Furthermore, malignant tumors can be primary or metastatic. Metastatic lesions are more common than primary tumors [30]. In intracranial tumors or brain tumors, each patient has different symptoms depending on the location of the tumor.…”

“…Management options include observational surveillance, surgical resection, chemotherapy, radiation therapy, or a combination thereof. No two intracranial tumors are the same, which means that no two intracranial tumors are managed the same [30]. Management of brain tumors is usually based on the pathophysiology and location of the lesion found.…”

“…Management of brain tumors is usually based on the pathophysiology and location of the lesion found. The location of the intracranial tumor along with its size and mass effect determines its clinical presentation [30]. However, in general there are several treatments that can be done:…”

Multimodal Medical Image Fusion Network Based on Target Information Enhancement

“…The growth of tumors can lead to the proliferation and harm of brain tissue in neighboring areas. Even benign tumors can exert significant pressure on brain tissue, causing highimpact complications [6][7]. Brain tumors account for about 2.17% of all cancer-related deaths, and their 5-year survival rate is only 5.6% [8].…”

Optimizing MRI-based brain tumor classification and detection using AI: A comparative analysis of neural networks, transfer learning, data augmentation, and the cross-transformer network

“…Brain tumors, while they rarely spread to other parts of the body, can still be dangerous as they can grow quickly and damage brain tissue as they diffuse to nearby areas. The growth can press on brain tissue, causing high-impact complications even if the tumors are benign [10] , [11] . Brain tumors account for approximately 2.17 % of all cancer deaths and the five-year survival rate is low, at around 5.6 % for glioblastoma [12] .…”